US2011150780A1PendingUtilityA1
Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
Est. expiryAug 21, 2016(expired)· nominal 20-yr term from priority
Inventors:Timothy J. KriegerRobert S. TaylorDouglas ErfleJanet R. FraserMichael H. P. WestPatricia J. Mcnichol
A61K 41/0028A61P 33/10A61P 31/12A61K 38/00A61P 33/06A61K 47/60A61P 31/00A61P 33/04A61P 33/02A61P 33/12A61P 31/10A61P 31/04C07K 14/001A61P 33/00C07K 7/08Y02A50/30
67
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compositions and methods for treating infections, especially bacterial infections, are provided. Indolicidin peptide analogues containing at least two basic amino acids are prepared. The analogues are administered as modified peptides, preferably containing photo-oxidized solubilizer.
Claims
exact text as granted — not AI-modified1 - 3 . (canceled)
4 . A method of treating or preventing a microbial infection, comprising administering to a patient a therapeutically effective amount of a composition comprising at least one indolicidin analogue of up to 35 amino acids that comprises one of the following sequences:
(SEQ ID NO: 25)
Lys Arg Arg Trp Pro Trp Trp Pro Trp Lys
Lys Leu Ile;
(SEQ ID NO: 23)
Ile Leu Arg Trp Pro Trp Trp Pro Trp Arg
Arg Lys;
(SEQ ID NO: 46)
Lys Arg Arg Trp Pro Trp Trp Pro Trp Arg
Leu Ile;
(SEQ ID NO: 47)
Ile Leu Arg Trp Pro Trp Trp Pro Trp Arg
Arg Lys Ile Met Ile Leu Lys Lys Ala Gly
Ser;
(SEQ ID NO: 24)
Ile Leu Arg Trp Pro Trp Trp Pro Trp Arg
Arg Lys Met Ile Leu Lys Lys Ala Gly Ser;
(SEQ ID NO: 48)
Ile Leu Arg Trp Pro Trp Trp Pro Trp Arg
Arg Lys Asp Met Ile Leu Lys Lys Ala Gly
Ser;
(SEQ ID NO: 26)
Trp Arg Ile Trp Lys Pro Lys Trp Arg Leu
Pro Lys Trp;
(SEQ ID NO: 59)
Ile Leu Lys Lys Trp Val Trp Trp Pro Trp
Arg Arg Lys;
(SEQ ID NO: 27)
Ile Leu Arg Trp Val Trp Trp Val Trp Arg
Arg Lys;
or
(SEQ ID NO: 60)
Lys Arg Arg Trp Val Trp Trp Val Trp Arg
Leu Ile.
5 . The method of claim 4 , wherein the indolicidin analogue comprises the sequence of Ile Leu Arg Trp Pro Trp Trp Pro Trp Arg Arg Lys (SEQ ID NO:23).
6 . The method of claim 4 , wherein the amino acid sequence of the indolicidin analogue consists of Ile Leu Arg Trp Pro Trp Trp Pro Trp Arg Arg Lys (SEQ ID NO:23).
7 . The method of claim 4 , wherein the microbial infection is due to a bacterium and wherein the composition is administered ex vivo.
8 . The method of claim 7 , wherein the composition is administered to the skin of the patient.
9 . The method of claim 4 , wherein the microbial infection is associated with nasal colonization.
10 . The method of claim 9 , wherein the composition is administered by aerosolization or spray.
11 . The method of claim 4 , wherein the microbial infection is a burn-related infection.
12 . The method of claim 4 , wherein the microbial infection is a surgical wound infection.
13 . The method of claim 4 , wherein the composition is a gel.
14 . The method of claim 6 , wherein the microbial infection is associated with nasal colonization.
15 . The method of claim 14 , wherein the composition is administered by aerosolization or spray.
16 . The method of claim 6 , wherein the microbial infection is a burn-related infection.
17 . The method of claim 6 , wherein the microbial infection is a surgical wound infection.
18 . The method of claim 6 , wherein the composition is a gel.
19 . The method of claim 4 , wherein the composition further comprises an antibiotic.
20 . The method of claim 4 , further comprising the step of administering an antibiotic.
21 . The method of claim 20 , wherein the antibiotic is minocycline, rifampin, cefazolin, vancomycin, teicoplanin, or a beta lactam.
22 . The method of claim 4 , wherein the microbial infection is due to a bacterium.
23 . The method of claim 22 , wherein the bacterium is antibiotic resistant.
24 . The method of claim 23 , wherein the antibiotic resistant bacteria is resistant to at least one of a penicillin, a cephalosporin, a fluoroquinolone, a macrolide, or an aminoglycoside.
25 . The method of claim 23 , wherein the antibiotic resistant bacteria is resistant to at least one of a tetracycline, a quinolone, a glycopeptide, a monobactam, a carbacephem, a carbapenem, or a cephamycin.
26 . The method of claim 23 , wherein the antibiotic resistant bacteria is resistant to at least one of methicillin, vancomycin, teicoplanin, ciprofloxacin, clindamycin, ampicillin, erythromycin, amikacin, ceftriaxone, gentamicin, mupirocin, piperacillin, or tobramycin.
27 . A method of inhibiting or preventing growth of a bacterium on a surface of an object, comprising coating the surface with a therapeutically effective amount of a composition comprising at least one indolicidin analogue of up to 35 amino acids that comprises one of the following sequences:
(SEQ ID NO: 25)
Lys Arg Arg Trp Pro Trp Trp Pro Trp Lys
Lys Leu Ile;
(SEQ ID NO: 23)
Ile Leu Arg Trp Pro Trp Trp Pro Trp Arg
Arg Lys;
(SEQ ID NO: 46)
Lys Arg Arg Trp Pro Trp Trp Pro Trp Arg
Leu Ile;
(SEQ ID NO: 47)
Ile Leu Arg Trp Pro Trp Trp Pro Trp Arg
Arg Lys Ile Met Ile Leu Lys Lys Ala Gly
Ser;
(SEQ ID NO: 24)
Ile Leu Arg Trp Pro Trp Trp Pro Trp Arg
Arg Lys Met Ile Leu Lys Lys Ala Gly Ser;
(SEQ ID NO: 48)
Ile Leu Arg Trp Pro Trp Trp Pro Trp Arg
Arg Lys Asp Met Ile Leu Lys Lys Ala Gly
Ser;
(SEQ ID NO: 26)
Trp Arg Ile Trp Lys Pro Lys Trp Arg Leu
Pro Lys Trp;
(SEQ ID NO: 59)
Ile Leu Lys Lys Tip Val Trp Trp Pro Trp
Arg Arg Lys;
(SEQ ID NO: 27)
Ile Leu Arg Trp Val Trp Trp Val Trp Arg
Arg Lys;
or
(SEQ ID NO: 60)
Lys Arg Arg Trp Val Trp Trp Val Trp Arg
Leu Ile.
28 . The method of claim 27 , wherein the indolicidin analogue comprises the sequence of Ile Leu Arg Trp Pro Trp Trp Pro Trp Arg Arg Lys (SEQ ID NO:23).
29 . The method of claim 27 , wherein the amino acid sequence of the indolicidin analogue consists of Ile Leu Arg Trp Pro Trp Trp Pro Trp Arg Arg Lys (SEQ ID NO:23).
30 . The method of claim 27 , further comprising the step of contacting the surface of the object with an antibiotic.
31 . The method of claim 30 , wherein the antibiotic is minocycline, rifampin, cefazolin, vancomycin, teicoplanin, or a beta lactam.
32 . The method of claim 27 , wherein the bacterium is antibiotic resistant.
33 . The method of claim 32 , wherein the antibiotic resistant bacteria is resistant to at least one of a penicillin, a cephalosporin, a fluoroquinolone, a macrolied, an aminoglycoside, a tetracycline, a quinolone, a glycopeptide, a monobactam, a carbacephem, a carbapenem, or a cephamycin.
34 . The method of claim 27 , wherein the object is a stent, tube, probe, cannula, catheter, synthetic vascular graft, blood monitoring device, artificial heart valve, or needle.
35 . The method of claim 27 , wherein the object is a tube.
36 . The method of claim 27 , wherein the object is a medical device.
37 . The method of claim 36 , wherein the medical device is a catheter.
38 . The method of claim 36 , wherein the medical device is an intravascular device.
39 . The method of claim 27 , wherein the bacteria is a Gram-negative bacteria selected from the group consisting of Enterobacter sp., E. coli, Klebsiella sp., and Acinetobacter sp.
40 . The method of claim 27 , wherein the bacteria is a Gram-positive bacteria selected from the group consisting of S. aureus , coagulase negative staphylococci, enterococci, S. epidermidis, S. pneumoniae , and Viridans Streptococci.
41 . The method of claim 27 , wherein the composition is a gel.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.